Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China.

Zhan-Miao YiPeng MenShuli QuChaoyun LiXin YuSuodi Zhai

Published in: Expert review of pharmacoeconomics & outcomes research (2020)

Amisulpride is likely to be a cost-effective option with increased effectiveness compared with olanzapine in the treatment of schizophrenia patients in China.

Keyphrases

bipolar disorder
end stage renal disease
randomized controlled trial
newly diagnosed
ejection fraction
systematic review
peritoneal dialysis
patient reported outcomes
combination therapy